Breaking News Instant updates and real-time market news.

KALA

Kala Pharmaceuticals

$13.38

-0.36 (-2.62%)

21:04
06/19/18
06/19
21:04
06/19/18
21:04

Kala Pharma's KPI-121 update suggests faster market entry, Wells Fargo says

Wells Fargo analyst David Maris kept his Outperform rating and $19 price target on Kala Pharmaceuticals, saying its announced plans to submit a new drug application for KPI-121 to the FDA in the second half of the year may expedite its market entry. The analyst adds that the most likely scenario is for the FDA to accept the company's NDA for review but ultimately consider the Stride 3 data and issue a Complete Response Letter for an additional study, which will likely lead to a class 2 resubmission and a shortened 6-month review period. Maris contends that it is also possible that the FDA "accepts Kala's NDA, finds the existing data to be sufficient, and approves KPI-121 0.25% in its first review cycle, leading to a late-2019 or early 2020 commercialization.

  • 24

    Aug

KALA Kala Pharmaceuticals
$13.38

-0.36 (-2.62%)

10/25/17
WELS
10/25/17
NO CHANGE
Target $24
WELS
Outperform
Kala new drug application an 'important milestone,' says Wells Fargo
Wells Fargo analyst David Maris calls Kala Pharmaceuticals' on-time new drug application for Inveltys an "important milestone" since the company is development-stage beginning the transition to a commercially-focused business. The topical has the potential to be the first FDA approved ocular corticosteroid with two-times per day dosing for the treatment of inflammation and pain following ocular surgery, Maris tells investors in a research note. He sees lower than average commercial and regulatory risk for Inveltys as the active steroid is well-known and already approved in postsurgical ocular pain and inflammation. He sees sales of the topical growing to $100M in 2021 and keeps an Outperform rating Kala with a $24 price target.
11/17/17
JPMS
11/17/17
NO CHANGE
Target $35
JPMS
Overweight
Kala offers 'compelling' risk/reward into dry eye data, says JPMorgan
After meeting with management, JPMorgan analyst Chris Schott continues to see a "compelling" risk/reward for Kala Pharmaceuticals shares ahead of Phase 3 data for KPI-121 0.25% reading out later this year. The shares can rally to $40-plus share on positive Phase 3 dry eye data, versus downside to high single digits or low teens on a negative readout, Schott tells investors in a research note. The analyst views Kala as an attractive ophthalmology pure play and keeps an Overweight rating on the shares with a $35 price target.
01/05/18
WELS
01/05/18
NO CHANGE
WELS
Outperform
Kala dry eye trial results mixed but positive, says Wells Fargo
After Kala Pharmaceuticals reported that KPI-121 demonstrated statistically significant improvements in the primary sign and symptom endpoints in one Phase 3 trial but missed for the primary symptom endpoint in another trial, Wells Fargo analyst David Maris said the mixed data "complicates things" but still show a positive drug profile for KPI-121. He would expect the shares to be down on this data, but also believes some of the risk seems to have been in expectations given the stock having been down recently. Maris keeps an Outperform rating on Kala shares, which are down 24% in morning trading.
01/25/18
WELS
01/25/18
NO CHANGE
Target $19
WELS
Outperform
Kala Pharmaceuticals price target lowered to $19 from $24 at Wells Fargo
Wells Fargo analyst David Maris lowered his price target for Kala Pharmaceuticals to $19 from $24 on valuation after the shares dropped following mixed results from the two pivotal Phase III trials of its dry eye treatment, KPI-121. The analyst believes Kala's shares have the opportunity to outperform as investors shift their near-term focus to the company's post-surgical ocular steroid which has an August 2018 PDUFA. He reiterates an Outperform rating on the stock.

TODAY'S FREE FLY STORIES

BIIB

Biogen

$319.85

-10.4 (-3.15%)

14:57
10/20/18
10/20
14:57
10/20/18
14:57
Conference/Events
Biogen to host conference call »

Chief Medical Officer…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 23

    Oct

  • 25

    Oct

SELB

Selecta Biosciences

$13.80

-1.34 (-8.85%)

14:13
10/20/18
10/20
14:13
10/20/18
14:13
Conference/Events
Selecta Biosciences to host conference call »

Management discusses the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

TROV

Trovagene

$1.12

-0.03 (-2.61%)

14:11
10/20/18
10/20
14:11
10/20/18
14:11
Conference/Events
Trovagene to host conference call »

Management provides an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SLS

Sellas Life Sciences

$1.56

-0.24 (-13.33%)

13:54
10/20/18
10/20
13:54
10/20/18
13:54
Conference/Events
Sellas Life Sciences to host conference call »

Management provides a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

  • 07

    Nov

NVS

Novartis

$87.19

0.95 (1.10%)

13:50
10/20/18
10/20
13:50
10/20/18
13:50
Conference/Events
Novartis to host conference call »

Management discusses the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 07

    Nov

UA

Under Armour

$16.79

-0.365 (-2.13%)

, UAA

Under Armour

$18.20

-0.42 (-2.26%)

12:43
10/20/18
10/20
12:43
10/20/18
12:43
Periodicals
Under Armour stock could triple, Barron's says »

Under Armour has had a…

UA

Under Armour

$16.79

-0.365 (-2.13%)

UAA

Under Armour

$18.20

-0.42 (-2.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

  • 30

    Oct

  • 27

    Nov

  • 03

    Mar

STZ

Constellation Brands

$222.98

-2.36 (-1.05%)

, CGC

Canopy Growth

$46.87

-1.99 (-4.07%)

12:37
10/20/18
10/20
12:37
10/20/18
12:37
Periodicals
Constellation Brands changing CEOs, not marijuana strategy, Barron's says »

Constellation Brands…

STZ

Constellation Brands

$222.98

-2.36 (-1.05%)

CGC

Canopy Growth

$46.87

-1.99 (-4.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Oct

  • 14

    Nov

CFG

Citizens Financial

$36.36

1.44 (4.12%)

, AAPL

Apple

$219.28

3.3 (1.53%)

12:33
10/20/18
10/20
12:33
10/20/18
12:33
Periodicals
Citizens Financial stock worth buying, Barron's says »

Citizens Financial (CFG)…

CFG

Citizens Financial

$36.36

1.44 (4.12%)

AAPL

Apple

$219.28

3.3 (1.53%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$153.95

-1 (-0.65%)

, AAPL

Apple

$219.28

3.3 (1.53%)

12:26
10/20/18
10/20
12:26
10/20/18
12:26
Periodicals
Netflix emerged as winner in new way to rank big tech stocks risk, Barron's says »

A year ago,…

FB

Facebook

$153.95

-1 (-0.65%)

AAPL

Apple

$219.28

3.3 (1.53%)

AMZN

Amazon.com

$1,763.91

-7.54 (-0.43%)

NFLX

Netflix

$332.69

-14.02 (-4.04%)

GOOG

Alphabet

$1,096.41

8.51 (0.78%)

GOOGL

Alphabet Class A

$1,104.66

7.43 (0.68%)

DIS

Disney

$118.81

2.55 (2.19%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 25

    Oct

  • 25

    Oct

  • 25

    Oct

  • 28

    Oct

  • 30

    Oct

  • 07

    Nov

  • 08

    Nov

  • 13

    Nov

  • 03

    Mar

BABA

Alibaba

$142.90

1.1 (0.78%)

, TCEHY

Tencent

$0.00

(0.00%)

12:17
10/20/18
10/20
12:17
10/20/18
12:17
Periodicals
Chinese internet giants down, not out, Barron's says »

Alibaba (BABA), Tencent…

BABA

Alibaba

$142.90

1.1 (0.78%)

TCEHY

Tencent

$0.00

(0.00%)

BIDU

Baidu

$191.93

0.1 (0.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Oct

  • 02

    Nov

BLK

BlackRock

$401.61

1.74 (0.44%)

, IVZ

Invesco

$22.00

0.74 (3.48%)

12:13
10/20/18
10/20
12:13
10/20/18
12:13
Periodicals
Fund companies sued by own employees over pricey 401k plans, Barron's says »

BlackRock (BLK),…

BLK

BlackRock

$401.61

1.74 (0.44%)

IVZ

Invesco

$22.00

0.74 (3.48%)

TROW

T. Rowe Price

$100.13

0.31 (0.31%)

SCHW

Charles Schwab

$46.81

0.11 (0.24%)

MTB

M&T Bank

$162.72

2.09 (1.30%)

MS

Morgan Stanley

$46.43

0.4 (0.87%)

JPM

JPMorgan

$107.92

-0.21 (-0.19%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 24

    Oct

  • 26

    Feb

JPM

JPMorgan

$107.92

-0.21 (-0.19%)

, BLK

BlackRock

$401.61

1.74 (0.44%)

12:04
10/20/18
10/20
12:04
10/20/18
12:04
Periodicals
Khashoggi case puts financial ties to Saudis under strain, Barron's says »

The suspected killing of…

JPM

JPMorgan

$107.92

-0.21 (-0.19%)

BLK

BlackRock

$401.61

1.74 (0.44%)

BX

Blackstone

$34.66

-0.61 (-1.73%)

AMC

AMC Entertainment

$19.81

0.18 (0.92%)

IMAX

Imax

$22.45

-0.11 (-0.49%)

SIX

Six Flags

$66.40

-1.16 (-1.72%)

WWE

WWE

$82.02

-1.49 (-1.78%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 24

    Oct

  • 24

    Oct

  • 25

    Oct

  • 13

    Nov

  • 14

    Nov

  • 26

    Feb

ABBV

AbbVie

$88.01

-1.93 (-2.15%)

, ALXN

Alexion

$125.96

-0.63 (-0.50%)

04:55
10/20/18
10/20
04:55
10/20/18
04:55
Conference/Events
The ACR and ARHP to hold annual meeting »

American College of…

ABBV

AbbVie

$88.01

-1.93 (-2.15%)

ALXN

Alexion

$125.96

-0.63 (-0.50%)

AMGN

Amgen

$201.75

-1.03 (-0.51%)

AUPH

Aurinia Pharmaceuticals

$5.56

-0.13 (-2.28%)

BMY

Bristol-Myers

$54.31

-1.7 (-3.04%)

CELG

Celgene

$82.42

-0.52 (-0.63%)

DGX

Quest Diagnostics

$102.49

0.12 (0.12%)

DNA

Bought by RHHBY

$0.00

(0.00%)

FLXN

Flexion

$18.96

0.33 (1.77%)

GILD

Gilead

$73.27

-0.9 (-1.21%)

GSK

GlaxoSmithKline

$40.87

1.25 (3.16%)

REGN

Regeneron

$389.94

-5.45 (-1.38%)

RARE

Ultragenyx

$63.33

-0.77 (-1.20%)

QDEL

Quidel

$64.68

-2.85 (-4.22%)

PFE

Pfizer

$44.50

0.48 (1.09%)

NVS

Novartis

$87.19

0.95 (1.10%)

MRK

Merck

$72.34

0.12 (0.17%)

MCK

McKesson

$132.36

-0.34 (-0.26%)

LLY

Eli Lilly

$111.91

-1.4 (-1.24%)

TMO

Thermo Fisher

$227.13

-2.51 (-1.09%)

TKPYY

Takeda Pharmaceutical

$0.00

(0.00%)

SELB

Selecta Biosciences

$13.80

-1.34 (-8.85%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

  • 20

    Oct

  • 22

    Oct

  • 22

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 24

    Oct

  • 24

    Oct

  • 25

    Oct

  • 25

    Oct

  • 25

    Oct

  • 25

    Oct

  • 25

    Oct

  • 28

    Oct

  • 29

    Oct

  • 30

    Oct

  • 30

    Oct

  • 31

    Oct

  • 02

    Nov

  • 06

    Nov

  • 06

    Nov

  • 06

    Nov

  • 07

    Nov

  • 09

    Nov

  • 27

    Nov

  • 11

    Jan

  • 16

    Feb

  • 18

    Feb

  • 28

    Apr

  • 13

    May

ABBV

AbbVie

$88.01

-1.93 (-2.15%)

, DCPH

Deciphera

$22.22

-4.97 (-18.28%)

04:55
10/20/18
10/20
04:55
10/20/18
04:55
Conference/Events
European Society for Medical Oncology (ESMO) to hold a conference »

ESMO 2018 Congress to be…

ABBV

AbbVie

$88.01

-1.93 (-2.15%)

DCPH

Deciphera

$22.22

-4.97 (-18.28%)

TSRO

Tesaro

$41.81

-1.19 (-2.77%)

IMGN

ImmunoGen

$7.44

-0.355 (-4.56%)

REGN

Regeneron

$389.94

-5.45 (-1.38%)

CRSP

Crispr Therapeutics

$36.02

-1.18 (-3.17%)

CLVS

Clovis

$26.41

-3.54 (-11.82%)

MRTX

Mirati Therapeutics

$40.04

-1.82 (-4.35%)

LOXO

Loxo Oncology

$160.01

-7.58 (-4.52%)

RHHBY

Roche

$0.00

(0.00%)

NCNA

NuCana

$18.90

1.9 (11.18%)

CRVS

Corvus Pharmaceuticals

$8.01

-0.1 (-1.23%)

NTGN

Neon Therapeutics

$8.88

0.56 (6.73%)

NKTR

Nektar

$48.23

-1.33 (-2.68%)

EXEL

Exelixis

$16.27

-0.25 (-1.51%)

AVEO

Aveo Pharmaceuticals

$2.50

-0.03 (-1.19%)

KURA

Kura Oncology

$14.38

-1.18 (-7.58%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

  • 20

    Oct

  • 22

    Oct

  • 22

    Oct

  • 24

    Oct

  • 28

    Oct

  • 30

    Oct

  • 01

    Nov

  • 01

    Nov

  • 02

    Nov

  • 02

    Nov

  • 06

    Nov

  • 07

    Nov

  • 10

    Nov

  • 26

    Nov

  • 27

    Nov

  • 24

    Dec

  • 14

    Jan

  • 28

    Apr

  • 13

    May

A

Agilent

$64.47

-1.28 (-1.95%)

, AGLE

Aeglea BioTherapeutics

$9.32

-0.58 (-5.86%)

04:55
10/20/18
10/20
04:55
10/20/18
04:55
Conference/Events
American Society of Human Genetics to hold a conference »

ASHG Conference 2018 will…

A

Agilent

$64.47

-1.28 (-1.95%)

AGLE

Aeglea BioTherapeutics

$9.32

-0.58 (-5.86%)

ALXN

Alexion

$125.96

-0.63 (-0.50%)

RHHBY

Roche

$0.00

(0.00%)

BMRN

BioMarin

$103.31

-0.52 (-0.50%)

BIO

Bio-Rad

$280.96

-3.23 (-1.14%)

MSFT

Microsoft

$108.55

0.01 (0.01%)

ILMN

Illumina

$313.31

-7.98 (-2.48%)

FLDM

Fluidigm

$7.49

-0.45 (-5.67%)

HZNP

Horizon Pharma

$19.07

-0.01 (-0.05%)

NVTA

Invitae

$12.86

-0.23 (-1.76%)

NSTG

NanoString

$15.18

-0.41 (-2.63%)

QGEN

Qiagen

$35.91

0.455 (1.28%)

DGX

Quest Diagnostics

$102.49

0.12 (0.12%)

RTRX

Retrophin

$25.34

0.24 (0.96%)

TMO

Thermo Fisher

$227.13

-2.51 (-1.09%)

WTKWY

Wolters Kluwer

$0.00

(0.00%)

ARQL

ArQule

$4.33

-0.38 (-8.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

  • 21

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 25

    Oct

  • 25

    Oct

  • 28

    Oct

  • 30

    Oct

  • 31

    Oct

  • 01

    Nov

  • 01

    Nov

  • 01

    Nov

  • 07

    Nov

  • 07

    Nov

  • 08

    Nov

  • 13

    Nov

  • 27

    Nov

  • 28

    Nov

  • 24

    Dec

  • 18

    Feb

  • 03

    Mar

CLBR

Caliburn International

$0.00

(0.00%)

18:27
10/19/18
10/19
18:27
10/19/18
18:27
Syndicate
Caliburn International files registration statement for proposed IPO »

Caliburn International…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$276.21

-0.12 (-0.04%)

18:10
10/19/18
10/19
18:10
10/19/18
18:10
General news
Saudi Arabia says Kashoggi killed after fight broke out in consulate, CNBC says 

Reference Link

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$276.21

-0.12 (-0.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CE

Celanese

$99.62

2.61 (2.69%)

18:02
10/19/18
10/19
18:02
10/19/18
18:02
Hot Stocks
Celanese raises prices on MIBK, MIBC by EUR120/MT in Europe »

Celanese announced it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

REGN

Regeneron

$389.94

-5.45 (-1.38%)

, SNY

Sanofi

$44.57

0.12 (0.27%)

17:57
10/19/18
10/19
17:57
10/19/18
17:57
Hot Stocks
Regeneron, Sanofi: FDA approves asthma indication for Dupixent »

Regeneron Pharmaceuticals…

REGN

Regeneron

$389.94

-5.45 (-1.38%)

SNY

Sanofi

$44.57

0.12 (0.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 19

    Oct

  • 20

    Oct

  • 23

    Oct

  • 28

    Oct

  • 29

    Oct

  • 06

    Nov

  • 28

    Jan

  • 22

    Mar

  • 28

    Apr

  • 13

    May

XLE

Energy Select Sector SPDR

$71.50

-0.67 (-0.93%)

, XLU

Utilities SPDR

$54.57

0.82 (1.53%)

17:55
10/19/18
10/19
17:55
10/19/18
17:55
General news
Week ending ETF Scorecard: Staples, Real Estate, Utilities lead rebound »

S&P500 SECTORS: …

XLE

Energy Select Sector SPDR

$71.50

-0.67 (-0.93%)

XLU

Utilities SPDR

$54.57

0.82 (1.53%)

IYR

DJ US Real Estate Index Fund

$77.83

0.63 (0.82%)

XLP

Consumer Staples Sector SPDR

$54.72

1.225 (2.29%)

XLY

Consumer Discretionary Sector SPDR

$106.34

-1.06 (-0.99%)

XLB

S&P Select Materials SPDR

$53.13

-0.36 (-0.67%)

XLF

Financial Select Sector

$26.66

0.08 (0.30%)

XLV

Health Care Select Sector SPDR

$91.48

-0.93 (-1.01%)

XLK

Technology Select Sector SPDR

$70.00

-0.04 (-0.06%)

XLI

Industrial Select Sector SPDR

$73.17

-0.31 (-0.42%)

GLD

SPDR Gold Trust

$116.01

0.11 (0.09%)

SLV

iShares Silver Trust

$13.74

0.05 (0.37%)

USO

United States Oil Fund

$14.72

0.155 (1.06%)

UNG

United States Natural Gas Fund

$26.81

0.19 (0.71%)

HYG

iShares iBoxx $ High Yield Corporate Bond

$84.90

0.04 (0.05%)

LQD

iShares iBoxx $ Investment Grade Corporate Bond

$112.69

-0.15 (-0.13%)

TLT

iShares 20+ Year Treasury Bond Fund

$113.73

-0.24 (-0.21%)

IEF

iShares 7-10 Year Treasury Bond ETF

$100.12

-0.12 (-0.12%)

SHY

iShares 1-3 Year Treasury Bond

$82.95

-0.035 (-0.04%)

IWD

iShares Russell 1000 Value

$122.17

0.08 (0.07%)

IWF

iShares Russell 1000 Growth

$145.19

-0.5 (-0.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INSW

International Seaways

$21.51

0.41 (1.94%)

17:53
10/19/18
10/19
17:53
10/19/18
17:53
Syndicate
Breaking Syndicate news story on International Seaways »

International Seaways…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MNR

Monmouth Real Estate

$15.49

0.08 (0.52%)

17:48
10/19/18
10/19
17:48
10/19/18
17:48
Hot Stocks
Monmouth Real Estate acquires industrial building in New Jersey for $85.25M »

Monmouth Real Estate…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Nov

TEUM

Pareteum

$2.47

-0.07 (-2.76%)

17:38
10/19/18
10/19
17:38
10/19/18
17:38
Syndicate
Breaking Syndicate news story on Pareteum »

Pareteum files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

  • 15

    Nov

TEUM

Pareteum

$2.47

-0.07 (-2.76%)

17:36
10/19/18
10/19
17:36
10/19/18
17:36
Syndicate
Breaking Syndicate news story on Pareteum »

Pareteum files $150M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

  • 15

    Nov

NOC

Northrop Grumman

$307.77

-0.445 (-0.14%)

, LMT

Lockheed Martin

$328.22

0.21 (0.06%)

17:33
10/19/18
10/19
17:33
10/19/18
17:33
Periodicals
Trump to meet CEOs of Boeing, Lockheed Martin, General Dynamics, Reuters reports »

President Donald Trump…

NOC

Northrop Grumman

$307.77

-0.445 (-0.14%)

LMT

Lockheed Martin

$328.22

0.21 (0.06%)

BA

Boeing

$356.28

-3 (-0.84%)

GD

General Dynamics

$190.43

-0.76 (-0.40%)

BAESY

BAE Systems

$0.00

(0.00%)

HON

Honeywell

$153.49

-1.73 (-1.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 23

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 30

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.